Gri Bio, INC. 8-K Filing
Ticker: GRI · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1824293
Sentiment: neutral
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2025-12-10 16:05:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20251210.htm (8-K) — 23KB
- ex991_pressreleasetoplined.htm (EX-99.1) — 25KB
- image_0.jpg (GRAPHIC) — 38KB
- val-20251210_g1.jpg (GRAPHIC) — 16KB
- val-20251210_g2.jpg (GRAPHIC) — 2KB
- 0001824293-25-000167.txt ( ) — 253KB
- val-20251210.xsd (EX-101.SCH) — 2KB
- val-20251210_lab.xml (EX-101.LAB) — 23KB
- val-20251210_pre.xml (EX-101.PRE) — 13KB
- val-20251210_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 10, 2025, GRI Bio, Inc. (the "Company") issued a press release announcing topline results from the Company's Phase 2a clinical trial investigating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by GRI Bio, Inc., dated December 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 10, 2025 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer